author-photo

Carlos L. Arteaga

Vanderbilt University
University of Texas Southwestern Medical Center
Vanderbilt University Medical Center

536

Papers

35924

Citations

Citation Trend

Filter By

Papers (536) Sort By

Journal Conference Others

FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors.

2021 Biochimica et Biophysica Acta
Show All
- Source
- Cite
- Save
Citations (0)
Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab.

2021 Cancer Discovery
Show All
- Source
- Cite
- Save
Citations (7)
Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors.

2021 Cell Reports
Show All
- Source
- Cite
- Save
Citations (2)
Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity

2021 Cancer Cell
Show All
- Source
- Cite
- Save
Citations (4)
530P Phase II study of PI3K inhibitor copanlisib in cancer patients with deleterious PTEN mutations and retained PTEN protein expression: Results from the NCI-MATCH Trial (EAY131) sub-protocol Z1H

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract GS1-06: FGFR1 associates with gene promoters and regulates gene transcription: Implications for endocrine resistance in ER+/FGFR1-amplified breast cancer

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830]

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Corrigendum to: The H1047R PIK3CA oncogene induces a senescence-like state, pleiotropy and acute HSP90 dependency in HER2+ mammary epithelial cells.

2021 Carcinogenesis
Show All
- Source
- Cite
- Save
Citations (0)
Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase 2 NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Reply to T. Shimoi et al and Y. Shimanuki et al.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)